• Screening and early diagnosis of hepatocellular carcinoma

Screening and early diagnosis of hepatocellular carcinoma

HEALTH OF WOMAN. 2018.3(129):70–76; doi 10.15574/HW.2018.129.70

Kirienko V. T. , Zaytsev I. A. , Grushkevich V. V. , Potii V. V.
Kiev National Medical University А.А. Bogomolets
National Military Medical Clinical Center, Main Military Clinical Hospital, Kiev
Donetsk State Medical University. M. Gorky, Lyman

Presents the risk factors for the development of hepatocellular carcinoma, the current possibilities for screening and early diagnosis of HCC with imaging techniques, non-invasive serological markers. The categories of patients subject to HCC screening and the examination algorithm are determined.
Key words: hepatocellular carcinoma, primary liver cancer, screening, early diagnosis.

REFERENCES

1. Siegel R et al. 2014. Cancer statistics. CA. Cancer J. Clin. 64(1):9–29. https://doi.org/10.3322/caac.21208; PMid:24399786

2. Ferlay J et al. 2015. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN2012. Int.J. Cancer. 136(5):E359-E386. https://doi.org/10.1002/ijc.29210; PMid:25220842

3. Tejeda-Maldonado J, García-Juárez I et al. 2015. Diagnosis and treatment of hepatocellular carcinoma. World J. Hepatol. 7:362–376. https://doi.org/10.4254/wjh.v7.i3.362; PMid:25848464 PMCid:PMC4381163

4. El-Serag HB, Kanwal F. 2014. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 60:1767–1775. https://doi.org/10.1002/hep.27222; PMid:24839253 PMCid:PMC4211957

5. Fedorenko ZP, Mykhailovych YuI, Hulak LO ta in. 2016. Rak v Ukraini, 2014–2015. Biul. Nats. kantser-reiestru Ukrainy. No. 17: 144.

6. Sunkara V, Hebert JR. 2016. The application of the mortality-to-incidence ratio for the evaluation of cancer care disparities globally. Cancer. 122:487–488. https://doi.org/10.1002/cncr.29746; PMid:26484652

7. Sunkara V, Hebert JR. 2015. The colorectal cancer mortality-to-incidence ratio as an indicator of global cancer screening and care. Cancer. 121:1563–1569. https://doi.org/10.1002/cncr.29228; PMid:25572676 PMCid:PMC4424055

8. Chen SL, Wang SC et al. 2017. Prostate cancer mortality-to-incidence ratios are associated with cancer care disparities in 35 countries. Sci Rep. 7:40003. https://doi.org/10.1038/srep40003; PMid:28051150 PMCid:PMC5209738

9. Wang SC, Sung WW et al. 2017. The gender difference and mortality-to-incidence ratio relate to health care disparities in bladder cancer: national estimates from 33 countries. Scientific reports. 7:4360. https://doi.org/10.1038/s41598-017-04083-z; PMid:28659584 PMCid:PMC5489533

10. Beasley RP, Hwang LY, Lin CC, Chien CS. 1981. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 2(8256):1129–33. https://doi.org/10.1016/S0140-6736(81)90585-7

11. Singal AG, Pillai A, Tiro A. 2014. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLOS One. 11(4):e1001624. https://doi.org/10.1371/journal.pmed.1001624

12. Siegel R, Naishadham D, Jemal A. 2013 Cancer statistics 2013. CA Cancer J Clin. 63(1):11–30. https://doi.org/10.3322/caac.21166; PMid:23335087

13. EASL–EORTC. 2012. Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology 56:908–943. https://doi.org/10.1016/j.jhep.2011.12.001; PMid:22424438

14. Perz JF, Armstrong GL, Farrington LA et al. 2006. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 45(4):529–38. https://doi.org/10.1016/j.jhep.2006.05.013; PMid:16879891

15. Parkin DM. 2006. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 118(12):3030–44. https://doi.org/10.1002/ijc.21731; PMid:16404738

16. Rosenthal E, Poiree M, Pradier C et al. 2003. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS. 17:1803–1809. https://doi.org/10.1097/00002030-200308150-00009; PMid:12891066

17. Perz JF, Armstrong GL, Farrington LA et al. 2006. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 45(4):529–38. https://doi.org/10.1016/j.jhep.2006.05.013; PMid:16879891

18. Liaw YF, Sung JJ, Chow WC et al. 2004. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351:1521–1531. https://doi.org/10.1056/NEJMoa033364; PMid:15470215

19. Stewart CJR, Coldewey J, Stewart IS. 2002. Comparison of fine needle aspiration cytology and needle core biopsy in the diagnosis of radiologically detected abdominal lesions. J Clin Pathol. 55:93-97. https://doi.org/10.1136/jcp.55.2.93; PMid:11865001 PMCid:PMC1769583

20. Arguedas MR, Chen VK et al. 2003. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am. J. Gastroenterol. 98:679–690. https://doi.org/10.1111/j.1572-0241.2003.07327.x

21. Hashem B, El-Serag HB. 2007. Epidemiology of hepatitis C-related hepatocellular carcinoma. Medscape. Medscape Gastroenterology. http: //www.medscape.com/viewarticle/560012

22. Bosch FX, Ribes J, Borras J. 1999. Epidemiology of primary liver cancer. Semin Liver Dis. 19:271-285. https://doi.org/10.1055/s-2007-1007117; PMid:10518307

23. Bruix J, Sherman M. 2005. Management of hepatocellular carcinoma. Hepatology 42:1208-1236. https://doi.org/10.1002/hep.20933; PMid:16250051

24. Wörns MA, Weinmann A et al. 2009. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 43(5):489–95. https://doi.org/10.1097/MCG.0b013e31818ddfc6; PMid:19247201

25. Yoshida H, Shiratori Y, Moriyama M et al. 1999. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and non-cirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med. 131(3):174–81. https://doi.org/10.7326/0003-4819-131-3-199908030-00003; PMid:10428733

26. Morgan RL, Baack B, Smith BD et al. 2013. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 158(5Pt1):329–37. https://doi.org/10.7326/0003-4819-158-5-201303050-00005; PMid:23460056

27. Levy I, Greig PD, Gallinger S et al. 2001. Resection of hepatocellular carcinoma without preoperative tumor biopsy. Ann. Surg. 234:206–209. https://doi.org/10.1097/00000658-200108000-00010; PMid:11505066 PMCid:PMC1422007

28. Gurusamy KS, Wilson R, Koretz RL et al. 2013. Is Sustained Virological Response a Marker of Treatment Efficacy in Patients with Chronic Hepatitis C Viral Infection with No Response or Relapse to Previous Antiviral Intervention? PLOS One. 8(12):e83313. https://doi.org/10.1371/journal.pone.0083313; PMid:24349487 PMCid:PMC3861485

29. Volk ML, Marrero JA. 2008. Early detection of liver cancer: diagnosis and management. Curr Gastroenterol Rep 10:60-66. https://doi.org/10.1007/s11894-008-0010-2

30. Fattovich G, Stroffolini T, Zagni I, Donato F. 2004. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127(5 Suppl. 1):S35–S50. https://doi.org/10.1053/j.gastro.2004.09.014; PMid:15508101

31. Shen YC, Hsu C, Cheng CC et al. 2012. A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression. Oncology 82(5):275–89. https://doi.org/10.1159/000337293; PMid:22555181

32. Shen YC, Hsu C, Cheng CC et al. 2012. A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression. Oncology 82(5):275–89. https://doi.org/10.1159/000337293; PMid:22555181

33. Mittal S, El-Serag HB. 2013. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 47(1):S2–S6. https://doi.org/10.1097/MCG.0b013e3182872f29; PMid:23632345 PMCid:PMC3683119

34. Torres DM, Harrison SA. 2012. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma. Semin Liver Dis. 32(1):30–38. https://doi.org/10.1055/s-0032-1306424; PMid:22418886

35. Wong R, Corley DA. 2008. Racial and ethnic variations in hepatocellular carcinoma incidence within the United States. Am J Med. 121(6):525–31. https://doi.org/10.1016/j.amjmed.2008.03.005; PMid:18501235

36. McGlynn KA, London WT. 2011. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 15(2):223–43. https://doi.org/10.1016/j.cld.2011.03.006.

37. Bruix J, Sherman M. 2005. Management of hepatocellular carcinoma. Hepatology 42:1208-1236. https://doi.org/10.1002/hep.20933; PMid:16250051

38. Takamatsu S, Noguchi N et al. 2008. Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma. Hepatogastroenterology. 55:609-614. PMid:18613418

39. Blonski W, Kotlyar DS, Forde KA. 2010. Non-viral causes of hepatocellular carcinoma. World J. Gastroenterol. 16:3603–3615. https://doi.org/10.3748/wjg.v16.i29.3603; PMid:20677332 PMCid:PMC2915420

40. Fattovich G, Stroffolini T, Zagni I, Donato F. 2004. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127(5 Suppl 1):S35-S50. https://doi.org/10.1053/j.gastro.2004.09.014; PMid:15508101

41. Manns MP, Czaja AJ, Gorham JD et al. 2010. Diagnosis and management of autoimmune hepatitis. Hepatology 51:2193-213. https://doi.org/10.1002/hep.23584; PMid:20513004

42. Beaton MD, Adams PC. 2006. Prognostic factors and survival in patients with hereditary hemochromatosis and cirrhosis. Can J Gastroenterol. 20:257-260. https://doi.org/10.1155/2006/428048

43. Bartlett DL, Di Bisceglie AM, Dawson LA. 2008. Cancer of the liver. In: DeVita J, V.T., Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 8th ed: Wolters Kluwer; Lippincott Williams & Wilkins.11291156.

44. Song do S, Bae SH. 2012. Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period. Clin Mol Hepatol. 18:258–267. https://doi.org/10.3350/cmh.2012.18.3.258; PMid:23091805 PMCid:PMC3467428

45. Davenport MS, Khalatbari S, Liu PS et al. 2014. Repeatability of diagnostic features and scoring systems for hepatocellular carcinoma by using MR imaging. Radiology 272:132–142. https://doi.org/10.1148/radiol.14131963; PMid:24555636 PMCid:PMC4263627

46. Bruix J, Sherman M. 2011. American Association for the Study of Liver Disease. Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022. https://doi.org/10.1002/hep.24199; PMid:21374666 PMCid:PMC3084991

47. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. 2012. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 56:908–43. https://doi.org/10.1016/j.jhep.2011.12.001; PMid:22424438

48. Hina Arif-Tiwari, Bobby Kalb, Surya Chundru et al. 2014. MRI of hepatocellular carcinoma: an update of current practices. Diagn Interv Radiol. 20:209–21. https://doi.org/10.5152/dir.2014.13370; PMid:24808419 PMCid:PMC4463351

49. Singal AG, Conjeevaram HS, Volk ML et al. 2012. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev. 21:793–9. https://doi.org/10.1158/1055-9965.EPI-11-1005; PMid:22374994 PMCid:PMC5640437

50. Digumarthy SR, Sahani DV, Saini S. 2005. MRI in detection of hepatocellular carcinoma (HCC). Cancer Imaging. 5:20–4. https://doi.org/10.1102/1470-7330.2005.0005; PMid:16154814 PMCid:PMC1665242

51. Sporea I, Badea R, Popescu A et al. 2014. Contrast–Enhanced Ultrasound (CEUS) for the evaluation of focal liver lesions – a prospective multicenter study of its usefulness in clinical practice. Ultraschall Med. https://doi.org/10.11152/mu.2014.2066.161.is1rs2; PMid:24563420

52. Sporea I, Martie A, Bota S et al. 2014. Characterization of focal liver lesions using contrast enhanced ultrasound as a first line method: a large monocentric experience. J Gastrointestin Liver Dis. 23:57–63. PMid:24689098

53. J.M. Llovet, M. 2012. DucreuxEASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma J Hepatol. 56: 908-943 https://doi.org/10.1016/j.jhep.2011.12.001; PMid:22424438

54. Kubota K, Ina H, Okada Y, Irie T. 2003. Growth rate of primary single hepatocellular carcinoma: determining optimal screening interval with contrast enhanced computed tomography. Dig Dis Sci. 48:581–586. https://doi.org/10.1023/A:1022505203786; PMid:12757173

55. Trinchet JC, Chaffaut C, Bourcier V et al. 2011. Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH). Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3– and 6-month periodicities. Hepatology 54:1987–97. https://doi.org/10.1002/hep.24545; PMid:22144108

56. Sigal A, Volk ML, Waljee A et al. 2009. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 30:37–47. https://doi.org/10.1111/j.1365-2036.2009.04014.x; PMid:19392863

57. Andersson KL, Salomon JA, Goldie SJ, Chung RT. 2008. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 6:1418–24. https://doi.org/10.1016/j.cgh.2008.08.005; PMid:18848905 PMCid:PMC4340842

58. Yu NC, Chaudhari V, Raman SS et al. 2011. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol. 9:161–7. https://doi.org/10.1016/j.cgh.2010.09.017; PMid:20920597

59. Lee KH, O’Malley ME, Haider MA, Hanbidge A. 2004. Triple-phase MDCT of hepatocellular carcinoma. AJR Am J Roentgenol. 182:643–9. https://doi.org/10.2214/ajr.182.3.1820643; PMid:14975963

60. Solomon R. 2008. Contrast-induced acute kidney injury: is there a risk after intravenous contrast? Clin J Am Soc Nephrol. 3:1242–3. https://doi.org/10.2215/CJN.03470708; PMid:18701610 PMCid:PMC4571161

61. Yu MH, Kim JH, Yoon JH et al. 2014. Radiology. Small (≤1 cm) Hepatocellular Carcinoma: Diagnostic Performance and Imaging Features at Gadoxetic Acid-enhanced MR Imaging. 271(3):748–60.

62. Bolondi L, Gaiani S, Celli N et al. 2005. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 42(1):27–34. https://doi.org/10.1002/hep.20728; PMid:15954118

63. Levy I, Greig PD, Gallinger S et al. 2001. Resection of hepatocellular carcinoma without preoperative tumor biopsy. Ann Surg. 234(2):206–9. https://doi.org/10.1097/00000658-200108000-00010; PMid:11505066 PMCid:PMC1422007

64. Purysko AS, Remer EM, Coppa CP et al. 2012. LI-RADS: a case-based review of the new categorization of liver findings in patients with end-stage liver disease. Radiographics 32:1977–95. https://doi.org/10.1148/rg.327125026; PMid:23150853

65. Khalili K, Kim TK, Jang HJ et al. 2011. Optimization of imaging diagnosis of 1–2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol. 54:723–8. https://doi.org/10.1016/j.jhep.2010.07.025; PMid:21156219

66. Ayuso C, Rimola J, Garcia-Criado A. 2012. Imaging of HCC. Abdom Imaging 37:215–30. https://doi.org/10.1007/s00261-011-9794-x; PMid:21909721

67. Hina Arif-Tiwari, Bobby Kalb, Surya Chundru et al. 2014. MRI of hepatocellular carcinoma: an update of current practices. Diagn Interv Radiol. 20:209–21. https://doi.org/10.5152/dir.2014.13370; PMid:24808419 PMCid:PMC4463351

68. Becker-Weidman DJ, Kalb B, Sharma P et al. 2011. Hepatocellular carcinoma lesion characterization: single-institution clinical performance review of multiphase gadolinium-enhanced MR imaging-comparison to prior same-center results after MR systems improvements. Radiology 261:824–33. https://doi.org/10.1148/radiol.11110157; PMid:21969663

69. Seale MK, Catalano OA, Saini S et al. 2009. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics 29:1725–48. https://doi.org/10.1148/rg.296095515; PMid:19959518

70. Catalano OA, Choy G, Zhu A et al. 2010. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. Radiology 254:154–62. https://doi.org/10.1148/radiol.09090304; PMid:20032150

71. Yan-Jie Zhao, Qiang JU, Guan-Cheng LI. 2013. Tumor markers for hepatocellular carcinoma (Review) Molecular and clinical oncology 1:593–8. https://doi.org/10.3892/mco.2013.119; PMid:24649215 PMCid:PMC3915636

72. Yamashita T, Forgues M, Wang W et al. 2008. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 68:1451–61. https://doi.org/10.1158/0008-5472.CAN-07-6013; PMid:18316609

73. Villanueva A, Minguez B, Forner A et al. 2010. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med. 61:317–28. https://doi.org/10.1146/annurev.med.080608.100623; PMid:20059340 PMCid:PMC3677155

74. Hoshida Y, Nijman SM, Kobayashi M et al. 2009. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 69:7385–92. https://doi.org/10.1158/0008-5472.CAN-09-1089; PMid:19723656 PMCid:PMC3549578

75. Lok AS, Sterling RK, Everhart JE et al. 2010. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 138:493-502. https://doi.org/10.1053/j.gastro.2009.10.031; PMid:19852963 PMCid:PMC2819612

76. Debruyne EN, Delanghe JR. 2008. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta. 385:19–26. https://doi.org/10.1016/j.cca.2008.05.010; PMid:18538135

77. Zhang BH et al. 2004. J Cancer Res Clin Oncol. 130:417–422. https://doi.org/10.1007/s00432-004-0552-0;https://doi.org/10.1007/s00432-004-0585-4; https://doi.org/10.1007/s00432-004-0613-4

78. Singhal A, Jayaraman M, Dhanasekaran DN, Kohli V. 2012. Molecular and serum markers in hepatocellular carcinoma: predictive tools for prognosis and recurrence. Crit Rev Oncol Hematol. 82:116–40. https://doi.org/10.1016/j.critrevonc.2011.05.005; PMid:21680198

79. Nakamura S, Nouso K et al. 2006. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol. 101:2038–43. https://doi.org/10.1111/j.1572-0241.2006.00681.x; PMid:16848811

80. Baek YH, Lee JH, Jang JS et al. 2009. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP. Hepatogastroenterology 56:763–67. PMid:19621698

81. Yamamoto K, Imamura H, Matsuyama Y et al. 2010. AFP, AFP-L3, DCP and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol. 45:1272–82. https://doi.org/10.1007/s00535-010-0278-5; PMid:20625772